Dicot Pharma AB (STO:DICOT)

Market Cap	753.40M -34.2%
Revenue (ttm)	n/a
Net Income	-75.24M
EPS	-0.04
Shares Out	3.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,922,955
Open	0.2160
Previous Close	0.2184
Day's Range	0.2100 - 0.2244
52-Week Range	0.1750 - 0.6270
Beta	0.82
Analysts	n/a
Price Target	n/a
Est. Earnings	Feb 12, 2027

About Dicot Pharma AB

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2015
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DICOT

Financial Performance

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 2, 2026

Data Sources Report a data error